Global Antibiotic R&D Partnership (GARDP)

💻 Join our #REVIVE Journal Club on 26 March for concise presentations on AI-enabled antibiotic discovery, gepotidacin phase 3 data in UTIs, the GAME CHANGER trial and antibiotic cross-resistance mapping.

🔗https://gotowebinar.pulse.ly/5e7aqfsjgm

@nazgulsakenova.bsky.social

Congrats to GSK for leading the #2026AMRBenchmark by Access to Medicines Foundation.

GARDP values collaboration that advances the development of new treatments for patients, while also supporting policy efforts and generating surveillance data to better understand and mitigate #AMR

📊 The 2026 Antimicrobial Resistance Benchmark highlights how collaboration can strengthen the #AMR global response spotlighting some of GARDP’s major SBIs, STIs & access projects.

👏 Thanks to the Access to Medicine Foundation for strengthening accountability across the sector.

🔗 bit.ly/4b167ij

Rights. Justice. Action. For ALL Women and Girls.

~50–60% women will develop a UTI in their lifetime & maternal sepsis accounts for ~1 in 10 maternal deaths globally. Quality-assured antibiotics must reach women across life stages & regions.

This #IWD2026, we centre equity in #AMR R&D & access.

📺 Recording now available

In collaboration with the CF AMR Syndicate, this recent #REVIVE webinar explores how to tackle chronic lung infections in cystic fibrosis through novel antimicrobials targeting Pseudomonas, Burkholderia and NTM.

🔗https://gardp.pulse.ly/8rubssf9oo

🧪GARDP has acquired data & licensing rights for the human use of apramycin, a potential treatment for drug-resistant Gram-negative infections.
With rights secured via Zurich University, a 2027 Phase 1 study is planned to assess safety & pharmacokinetics in humans.
🔗https://bit.pulse.ly/9shbh5zy0j

🤝 GARDP and Roche have signed a Memorandum of Understanding (MoU) to exchange expertise and perspectives on pathways to advance sustainable global access to innovative antibiotics.

#AMR

We’re hiring a Senior Legal Officer
📍 Geneva, Switzerland (Hybrid)

Support strategic negotiations and drafting of collaboration, license, manufacturing & clinical trial agreements across BD, Global Access & R&D.

🗓️ Apply by 15 March 2026.

#AMR #GlobalHealth #LegalCareers

Our team is speaking on China’s AMR landscape, antimicrobial business models and coordinated procurement.

Come say hello to us at Booth 22 🤝

We’ll be at #AMRConference2026 in Basel, Switzerland
📍 Congress Center Basel | 📅 Mar 3–4 | 📌 Booth 22

Co-organized by BEAM Alliance & bamconn, the conference spans the full AMR innovation chain, from research to market access.

📢 Registration is open for the 13 March REVIVE webinar on Clostridioides difficile prevention, therapy & R&D. This webinar is organized in collaboration with the Peggy Lillis Foundation.

📅 13 March 2026 | 🕒 17:00–18:30 CET

🔗 Register: https://gotowebinar.pulse.ly/ylrqzqrzxy

Huge congratulations to @dndi.org and all partners on this landmark achievement for people affected by sleeping sickness!

A powerful reminder of what long-term collaboration and scientific determination can achieve for global health 🌍🤝

📊 Key findings:

• Gonorrhoea prevalence was 1.0% in pregnant women and 9.4% in key populations (at higher risk for STIs)

• Chlamydia prevalence was high in both groups: 9.6% in pregnant women and 11.2% in key populations

#STIs #GlobalHealth #AMR #PublicHealth

Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections and associated risk factors among pregnant women and key populations in Kenya: A multi-centre cross-sectional study Sexually-transmitted pathogens Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) cause curable but often asymptomatic bacterial infections. Missed diagnoses and treatment, leading to chronic infections, can cause clinical complications and increase transmission. Accurate prevalence estimates are essential for the effective public health control of these sexually transmitted infections, especially in Africa, where data are scarce. This cross-sectional study was undertaken across five sites in Nairobi, Mombasa, and Homabay in Kenya. Between February and July 2022, vaginal, urethral, or rectal swab samples were collected in pregnant women and populations at higher risk of sexually transmitted infections (key populations) aged ≥15 years and analysed using an NG/CT nucleic acid amplification test. The primary objective was to determine the prevalence of NG and CT in pregnant women and key populations in Kenya to provide input in developing national prevalence estimates. Multivariate regression analysis examined infection status based on participants characteristics. NG prevalence was significantly lower among pregnant women [1.0% (95%CI: 0.5-1.9)] compared to key populations [9.4% (95%CI: 6.9-12.5)], while CT prevalence was similar between the two populations: 9.6% (95%CI: 7.8-11.7) in pregnant women and 11.2% (95%CI: 8.4-14.5) in key populations. NG and CT prevalence were highest among younger individuals, reaching 5.7% and 15.1% in pregnant women <20 years and 25.0% and 50.0% in key populations <20 years, respectively. Prevalence of both pathogens decreased with increasing age. These findings support the development of national prevalence estimates, which will support better management of NG and CT infections in Kenya by directing preventive and control measures.

📢 New publication in @plos.org Global Public Health

GARDP, in collaboration with the Ministry of Health of Kenya and @dndi.org, conducted a multi-center prevalence study for Chlamydia trachomatis and Neisseria gonorrhoeae across Kenya.

🔗 https://bit.pulse.ly/odp2iikyqo

@icarsglobal.bsky.social I @novo-nordisk.bsky.social I @carb-x.bsky.social I @lifearc.bsky.social I @gatesfoundation.bsky.social I @eupohamr.bsky.social

🔬 GARDP’s Dr Yann Ferrisse participated in the India AMR Innovation Workshop, contributing to discussions on building a coordinated AMR innovation ecosystem and funding architecture.

Collaboration will be key to advancing global AMR response.

#AMR #GlobalHealth

📢 Thailand’s FDA to review the new drug registration dossier for zoliflodacin, a first-in-class oral antibiotic for uncomplicated urogenital gonorrhoea.

As the first LMIC to enter review, access could follow within months versus decades, echoing GARDP’s mission for access in LMICs.

Statement on Brazil’s draft National Action Plan for Antimicrobial Resistance | GARDP português  │ español RIO DE JANEIRO, Brazil, 10 February 2026 - Antimicrobial resistance (AMR) is a rapidly accelerating global health crisis that threatens a c

📑We welcome Brazil’s draft AMR National Action Plan
With 30,000+ deaths annually linked to drug-resistant infections in Brazil, sustained & coordinated action is essential. Together with @dndi.org, we emphasize the need for collaboration, access & stewardship.

🔗 https://bit.pulse.ly/z9sjrcq36q

🔗Read more about the new experts here: revive.gardp.org/the-experts/

🌍🔬 In 2025, REVIVE welcomed 17 new experts to its global network supporting antimicrobial R&D.

Together with over 200 specialists across discovery, development and access, they help accelerate innovation against drug-resistant infections.

#AMR #AntibioticInnovation #GlobalHealth #REVIVE

(1/2) “We are at a dangerous tipping point with drug-resistant infections – global insecurity makes it worse,” writes
Manica Balasegaram in our latest op-ed

More below 👇
www.telegraph.co.uk/global-healt...

🔔 REVIVE webinar | 19 Feb

This session co-organized with CF AMR Syndicate focuses on chronic lung infections in cystic fibrosis and the challenges of developing new antibacterial treatments for persistent, drug-resistant infections.

🔗 Register: https://gotowebinar.pulse.ly/qm8wxastil

#REVIVE

Around 600 babies in Kenya will take part in this landmark trial, which also forms part of the EU funded, Penta-led SNIP-AFRICA consortium which aims to reduce mortality among newborns with sepsis in African hospitals.

📢 NEWS: Kenya joins GARDP’s NeoSep1 Part 2 trial on #NeonatalSepsis.

The trial has started enrolling newborn babies with sepsis at Kilifi County Hospital (Kilifi) Coast General Teaching & Referral Hospital (Mombasa) and Mbagathi Hospital (Nairobi).

Published during the Munich Security Conference, Manica Balasegaram’s op-ed in The Telegraph explains how conflict, climate change and global instability are driving the rise of drug-resistant infections, and why AMR must be part of the discussions.

🔗 bit.ly/3OgF0qy

@telegraph.co.uk

“This recognition belongs to everyone at GARDP and to the extraordinary network of partners, donors, researchers, trial participants and country teams who made this public-private partnership possible,” said Dr Balasegaram.

TIME highlights GARDP’s central role in advancing zoliflodacin, a first-in-class treatment for uncomplicated urogenital gonorrhoea approved by the US FDA in December 2025.

🔗 GARDP statement: gardp.org/dr-manica-ba...

#GlobalHealth #AntimicrobialResistance

This recognition reflects years of collective work at GARDP to develop new antibiotics through a not-for-profit model focused on equitable access.

🌍🏆 Dr Manica Balasegaram has been named one of TIME’s 100 most influential people in health for advancing and expanding access to new antibiotic treatments so as to tackle antimicrobial resistance.

🔗 Read the TIME feature: time.com/collections/...

#TIME100

👩 On the International Day of Women and Girls in Science, Astrid Pentz-Murr reflects on how women’s scientific leadership strengthens antibiotic R&D and drives real public health impact.

At GARDP, supporting women in science is central to advancing better solutions to #AMR.

@astridpm.bsky.social